Bio

Bio


Diana V. Do, MD, is a Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine.

She is an internationally recognized physician who specializes in the surgical and medical treatment of retinal disorders. Dr. Do is a board-certified ophthalmologist and is an expert in the management of age related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, retinal infections, and epiretinal membrane. She incorporates state-of-the-art treatment options for her patients while treating each individual with compassion and dignity. Her goal is to provide the highest level of care for each patient.

Dr. Do is a leading clinician-scientist who has authored over 150 publications in the medical literature and has contributed to over 25 book chapters. She has been the principal investigator and co-investigator on more than 45 clinical trials investigating novel treatments for retinal diseases and ocular inflammation. She has been an invited lecturer throughout the North and South America, Europe, and Asia. Furthermore, she has directed and participated in many continuing medical education courses for ophthalmologists and retina specialists throughout the United States.

Before joining Stanford, Dr. Do was Associate Professor of Ophthalmology at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine in Baltimore, Maryland. At Hopkins, she was Head of the Retina Fellowship Training Program. After her tenure at Johns Hopkins, she was recruited to serve as Vice Chair of Education and Professor of Ophthalmology at the University of Nebraska College of Medicine. In addition, she was Program Director of the ophthalmology residency training program and Director of the Retinal Fellowship Training Program at Nebraska.

Dr. Do was educated at the University of California at Berkeley where she graduated summa cum laude with a Bachelor of Arts in Molecular and Cellular Biology. She received her medical degree (Alpha Omega Alpha) and was a Regents Scholar at the University of California San Francisco School of Medicine. After completing her medicine internship at Massachusetts General Hospital / Harvard Medical School, she pursued both her ophthalmology training and retina fellowship at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine.

Her academic achievements have been recognized with numerous national awards including the Heed Ophthalmic Foundation Clinician-Scientist Award, the Ronald Michels Fellowship Foundation Award, the Honor Award from the American Society of Retina Specialists, and the Achievement Award from the American Academy of Ophthalmology.

Dr. Do has an active clinical and surgical practice while she continues to investigate novel treatments for retinal diseases. In addition, she teaches students, residents, and retina fellows at Stanford.

Clinical Focus


  • Retina
  • Ophthalmology

Academic Appointments


Administrative Appointments


  • Professor, Stanford University (2017 - Present)
  • Physician Improvement Leader, Byers Eye Institute, Stanford University (2018 - Present)

Honors & Awards


  • Ophthalmology Faculty Teaching Award, Byers Eye Institute, Stanford University (June 2018)
  • Honor Award, American Society of Retina Specialists (2016)
  • President's Award, Maryland Society of Eye Physicians and Surgeons (2010)
  • Achievement Award, American Academy of Ophthalmology (2008)
  • Young Investigator Award, International Michelson Symposium (2007)
  • Heed Clinician-Scientist Fellowship Award, Heed Ophthalmic Foundation (2004)
  • Ronald G. Michels Fellowship, Ronald G. Michels Foundation (2004)
  • Alpha Omega Alpha, Alpha Omega Alpha Honor Society (1999)
  • Regents Scholarship, University of California San Francisco School of Medicine (1995-1999)
  • I.L. Chaikoff Award, University of California, Berkeley (1995)
  • Phi Beta Kappa, Phi Beta Kappa Organization (1995)

Boards, Advisory Committees, Professional Organizations


  • Member, Macula Society (2014 - Present)
  • Member, American Society of Retina Specialists (2009 - Present)
  • Member, American Academy of Ophthalmology (2003 - Present)
  • Member, ARVO (2003 - Present)
  • Member, Alpha Omega Alpha Medical Honor Society (1998 - Present)

Professional Education


  • Fellowship:Wilmer Eye Institute Ophthalmology Residency (2005) MD
  • Residency:Wilmer Eye Institute Ophthalmology Residency (2003) MD
  • Board Certification: Ophthalmology, American Board of Ophthalmology (2012)
  • Retina Fellowship, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Surgical and Medical Retina (2005)
  • Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Ophthalmology Residency (2003)
  • Internship, Massachusetts General Hospital, Harvard Medical School, Internal Medicine (2000)
  • Internship:Massachusetts General Hospital (2000) MA
  • MD, University of California San Francisco School of Medicine, Medicine (1999)
  • Medical Education:University of California - San Francisco (1999) CA
  • BA, University of California, Berkeley, Molecular and Cellular Biology (1995)

Teaching

Stanford Advisees


Publications

All Publications


  • Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies. Ophthalmology Nguyen, Q. D., Merrill, P. T., Sepah, Y. J., Ibrahim, M. A., Banker, A., Leonardi, A., Chernock, M., Mudumba, S., Do, D. V. 2018

    Abstract

    In recent decades, the treatment paradigm for noninfectious intermediate uveitis, posterior uveitis, and panuveitis, a group of intraocular inflammatory diseases, has included systemic and local (periocular or intraocular) corticosteroids, biologics, and other steroid-sparing immunomodulatory therapy agents. Recently, an intravitreal formulation of sirolimus, an immunosuppressant that inhibits the mammalian target of rapamycin, a key regulator of cell growth in the immune system, was developed. On the basis of this mechanism and the local method of delivery, it was hypothesized that intravitreal sirolimus can improve ocular inflammation in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis, with minimal systemic exposure and systemic adverse events (AEs). This review summarizes the pharmacokinetics, efficacy, and safety results of intravitreal sirolimus from 3 preclinical studies and 4 phase 1-3 clinical studies. Preclinical studies in rabbits showed that 22 to 220 mug intravitreal sirolimus results in sustained release of sirolimus in the vitreous for 2 months or more, with systemic concentrations below the threshold for systemic immunosuppression (approximately 8 ng/ml). Subsequently, 2 phase 1 studies (n= 50 and n= 30) established that intravitreal sirolimus improves ocular inflammation in humans. Further investigation in phase 2 and 3 studies (n= 24 and n= 347, respectively) suggested that 440 mug has the best benefit-to-risk profile. In the phase 3 study, the proportion of patients who showed complete resolution of ocular inflammation at month 5 was significantly higher in the 440-mug group than in the 44-mug group (22.8% vs. 10.3%; P= 0.025, Fisher exact test). In addition, 47 of 69 patients (68.1%) who were treated with systemic corticosteroids at baseline discontinued corticosteroid use at month 5. No sirolimus-related systemic AEs were reported in phase 1-3 studies. Collectively, these preclinical and clinical study data of intravitreal sirolimus support the therapeutic rationale of treating noninfectious uveitis with a local mammalian target of rapamycin inhibitor and suggest that 440 mug intravitreal sirolimus has the potential to be an effective and well-tolerated anti-inflammatory and corticosteroid-sparing treatment for noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

    View details for DOI 10.1016/j.ophtha.2018.06.015

    View details for PubMedID 30060978

  • Trend in Utilizing Wide-Field Fundus Photography in Ophthalmology Huang, L. C., Do, D. V. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Posterior Segment Inflammatory Outcomes (Month-6) in the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Non-Infectious Uveitis Sadiq, M., Hassan, M., Halim, M., Afridi, R., Do, D. V., Quan Dong Nguyen, Sepah, Y. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Low Luminance Deficits in Retinal Disease Bodnar, Z., Shields, R., Dobrota, S., Do, D. V. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Baseline characteristics associated with good visual acuity outcomes in myopic choroidal neovascularization: results from the RADIANCE trial Pan, C., Do, D. V., Hill, L., Ecoiffier, T., Stoilov, I. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • RPGR-associated retinitis pigmentosa display unique outer retinal and choroidal vascular changes on optical coherence tomography angiography Tang, P., Tsang, S., Bassuk, A., Do, D. V., Mahajan, V. B. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2018
  • Rethinking Management Strategies for Proliferative Diabetic Retinopathy OPHTHALMIC SURGERY LASERS & IMAGING RETINA Tang, P. H., Hariprasad, S. M., Do, D. V. 2018; 49 (4): 224-+

    View details for DOI 10.3928/23258160-20180329-01

    View details for Web of Science ID 000430534800001

    View details for PubMedID 29664976

  • Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography. International journal of retina and vitreous Sarwar, S., Hassan, M., Soliman, M. K., Halim, M. S., Sadiq, M. A., Afridi, R., Agarwal, A., Do, D. V., Nguyen, Q. D., Sepah, Y. J. 2018; 4: 37

    Abstract

    Background: Vessel flow density (VFD) may provide important information regarding perfusion status. Diurnal variation in VFD of choriocapillaris has not been reported in literature. In the index study, optical coherence tomography angiography (OCTA) was used to assess the diurnal variation of the VFD in the choriocapillaris of subjects with no known ocular disease.Methods: Fifty eyes with no known ocular disease (25 subjects) were included. OCTA images were acquired using AngioVue (Optovue, Fremont, CA, USA) at two different time points on a single day: 9:00 AM and 6:00 PM. Macular cube scan protocol (3*3mm) centered on the fovea was used. Automatic segmentation of the retinal layers and choriocapillaris was performed using ReVue software, which was also used to measure the choriocapillaris VFD. Horizontal line scan passing through fovea was obtained by the device at both time points to measure the subfoveal choroidal thickness (CT). Linear measurement tool of software was used to measure subfoveal CT according to a standardized reproducible method. Wilcoxon signed-rank test was used to assess the differences in choriocapillaris VFD and subfoveal CT at the two time points. Correlation between change in choriocapillaris VFD and subfoveal CT at the two time points was assessed using the Pearson correlation coefficient (r).Results: The mean age of the subjects was 31.96±11.23years. Choriocapillaris VFD was significantly higher at 9:00 AM compared to 6:00 PM (P<0.0001) with mean choriocapillaris VFD of 68.74±4.80% at 9:00 AM and 67.57±5.41% at 6:00 PM, with a mean diurnal amplitude of 1.17%. Mean subfoveal CT was 287.74±61.51m at 9:00 AM and 270.06±60.73m at 6:00 PM. Subfoveal CT was also significantly higher at 9:00 AM compared to 6:00 PM (P<0.0001) with a mean diurnal amplitude of 17.68m. Change in choriocapillaris VFD correlated with change in subfoveal CT (r=0.87, P<0.001).Conclusion: OCTA demonstrated significant diurnal change in choriocapillaris VFD in subjects without any ocular disease with VFD being higher in the morning and lower in the evening. Decrease in choriocapillaris VFD in the evening correlated with a reduction in subfoveal CT.

    View details for DOI 10.1186/s40942-018-0140-0

    View details for PubMedID 30338130

  • Epidemiology and clinical features of inflammatory retinal vascular occlusions: pooled data from two tertiary-referral institutions CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY Agarwal, A., Karkhur, S., Aggarwal, K., Invernizzi, A., Singh, R., Dogra, M. R., Gupta, V., Gupta, A., Do, D. V., Nguyen, Q. D. 2018; 46 (1): 62–74

    Abstract

    In a subset of patients with retinal vasculitis, there is occlusion of blood flow through the retinal vessels. These eyes are at high risk of sight-threatening complications.To characterize epidemiology, clinical course, treatment and outcomes of occlusive retinal vasculitis (ORV).Retrospective study PARTICIPANTS: Seventy-seven uveitis patients with ORV at two large tertiary-care institutions (the USA and India).Out of 2438 patients screened, 346 patients were diagnosed with retinal vasculitis of which 77 patients (96 eyes) were diagnosed with ORV. Patients with ORV (capillary, arteriolar and/or venular) were further analysed. Diagnostic criteria for occlusive vasculitis included (i) absence of blood flow in vessels (arterioles, venules and/or capillaries), (ii) capillary non-perfusion areas and/or arteriolar-venous anastomosis and (iii) intraretinal haemorrhages, cotton-wool spots or vitreous haemorrhage.Best-corrected visual acuity, treatment and complications.The mean age was 32.09 ± 13.51 years. Most common aetiologies were tuberculosis and Adamantiades-Behçet's disease in India and systemic lupus erythematosus in the USA. Best-corrected visual acuity improved from 0.38 ± 0.30 logMAR (20/48 Snellen equivalent) (baseline) to 0.25 ± 0.30 (20/35 Snellen equivalent) at final visit (P < 0.0001). Vitreous haemorrhage was seen in 31.08% eyes. Pars plana vitrectomy was performed in 12.16% eyes. Therapy with systemic steroids was required in 78.48% patients. In addition, 46.75% patients required immunomodulators and/or biologics.Occlusive retinal vasculitis is caused by heterogeneous group of uveitides depending upon the geographic location. It is imperative to identify eyes with ORV as they are predisposed to complications requiring aggressive therapy.

    View details for DOI 10.1111/ceo.12997

    View details for Web of Science ID 000425459600009

    View details for PubMedID 28557287

  • Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis AMERICAN JOURNAL OF OPHTHALMOLOGY Sepah, Y., Sadiq, M., Chu, D. S., Dacey, M., Gallemore, R., Dayani, P., Hanout, M., Hassan, M., Afridi, R., Agarwal, A., Halim, M., Do, D. V., Quan Dong Nguyen 2017; 183: 71–80

    Abstract

    To report the primary endpoint analyses of the safety and efficacy of 2 different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.Randomized, controlled, multicenter clinical trial.STOP-Uveitis is a randomized, open-label safety, efficacy, and bioactivity clinical trial conducted at 5 clinical centers across the United States. The study evaluated the role of TCZ in patients with noninfectious uveitis (NIU). Thirty-seven patients with NIU were randomized into one of 2 treatment groups in a ratio of 1:1. Group 1 received IV infusions of 4 mg/kg TCZ and group 2 received IV infusions of 8 mg/kg TCZ. Infusions were given every 4 weeks in both groups until month 6 (primary endpoint). Primary outcome measure was incidence and severity of systemic and ocular adverse events through month 6. Secondary outcome measures included mean change in visual acuity (VA), vitreous haze (VH), and central macular thickness (CMT) at month 6.A total of 37 patients were randomized in the study. At month 6, 43.5% of patients who had the potential for a 2-step decrease in VH demonstrated a 2-step decrease (40% in Group 1 and 46.1% in Group 2). Mean change in CMT was -83.88 ± 136.1 μm at month 6 (-131.5 ± 41.56 μm in Group 1 and -38.92 ± 13.7 μm in Group 2). Mean change in VA was +8.22 ± 11.83 ETDRS letters at month 6 (10.9 ± 14.6 in Group 1 and 5.5 ± 7.8 in Group 2). Repeated infusions of TCZ were well tolerated.Repeated IV administrations of TCZ are well tolerated. TCZ (both 4 and 8 mg/kg) is effective in improving VA and reducing VH and CMT in eyes with noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

    View details for DOI 10.1016/j.ajo.2017.08.019

    View details for Web of Science ID 000414723100010

    View details for PubMedID 28887113